Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity

The coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2, has recently emerged worldwide. In this context, there is an urgent need to identify safe and effective therapeutic strategies for treatment of such highly contagious disease. We recently reported promising results of combining hydroxychloroquine and azithromycin as an early treatment option. Although ongoing clinical trials are challenging the efficacy of this combination, many clinicians claim the authorization to or have already begun to use it to treat COVID-19 patients worldwide. The aim of this article is to share pharmacology considerations contributing to the rationale of this combination, and to provide safety information to prevent toxicity and drug–drug interactions, based on available evidence.

[1]  A. Savarino,et al.  Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention , 2020, European Journal of Drug Metabolism and Pharmacokinetics.

[2]  P. Bhargava,et al.  Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 , 2020, International Journal of Infectious Diseases.

[3]  C. Marquette,et al.  QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS‐CoV‐2 Lower Respiratory Tract Infection , 2020, Clinical pharmacology and therapeutics.

[4]  D. Raoult,et al.  Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis , 2020, Travel Medicine and Infectious Disease.

[5]  L. Fabbri,et al.  Electrocardiographic features of patients with COVID-19 pneumonia , 2020, European Journal of Internal Medicine.

[6]  A. Perelson,et al.  Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load , 2020, CPT: pharmacometrics & systems pharmacology.

[7]  F. Scaglione,et al.  Macrolides and viral infections: focus on azithromycin in COVID-19 pathology , 2020, International Journal of Antimicrobial Agents.

[8]  P. Fournier,et al.  Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world , 2020, New Microbes and New Infections.

[9]  J. Hardin,et al.  Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19 , 2020, Med.

[10]  David R. Holtgrave,et al.  Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State , 2020, The Journal of Emergency Medicine.

[11]  G. Hripcsak,et al.  Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 , 2020, The New England journal of medicine.

[12]  S. Viskin,et al.  Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019 , 2020, Heart Rhythm.

[13]  P. Zimetbaum,et al.  Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.

[14]  Michael A. Spinelli,et al.  QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin , 2020, Heart Rhythm.

[15]  A. Savarino,et al.  Pharmacokinetic bases of the hydroxychloroquine response in COVID-19: implications for therapy and prevention , 2020, medRxiv.

[16]  D. Raoult,et al.  In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect , 2020, Microbial Pathogenesis.

[17]  André Machado Siqueira,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[18]  E. Chorin,et al.  The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin , 2020, Nature Medicine.

[19]  Erika K Wallender,et al.  Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing , 2020, Clinical pharmacology and therapeutics.

[20]  G. Hripcsak,et al.  Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study , 2020, medRxiv.

[21]  D. Roden,et al.  Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment , 2020, Journal of the American College of Cardiology.

[22]  J. Healey,et al.  Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society , 2020, Canadian Journal of Cardiology.

[23]  A. Perelson,et al.  Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load , 2020, medRxiv.

[24]  S. Lazar,et al.  Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol , 2020, European heart journal. Acute cardiovascular care.

[25]  E. Behr,et al.  SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes , 2020, Heart Rhythm.

[26]  Zhan Zhang,et al.  Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.

[27]  Hongming Miao,et al.  Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study , 2020, Signal Transduction and Targeted Therapy.

[28]  Samarth Sandeep,et al.  Energetics Based Modeling of Hydroxychloroquine and Azithromycin Binding to the SARS-CoV-2 Spike (S)Protein - ACE2 Complex , 2020 .

[29]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[30]  Zhìhóng Hú,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[31]  Simon Redwood,et al.  Coronaviruses and the cardiovascular system: acute and long-term implications , 2020, European heart journal.

[32]  Wu Zhong,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[33]  D. Raoult,et al.  New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? , 2020, International Journal of Antimicrobial Agents.

[34]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  X. de Lamballerie,et al.  Of chloroquine and COVID-19 , 2020, Antiviral Research.

[36]  Alexis Jacquier,et al.  Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study , 2020, Travel Medicine and Infectious Disease.

[37]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[38]  L. Zhang,et al.  [Adrenal hemorrhage in a patient with systemic lupus erythematosus]. , 2019, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences.

[39]  F. Hayden,et al.  Macrolides in critically ill patients with Middle East Respiratory Syndrome , 2019, International Journal of Infectious Diseases.

[40]  L. Cai,et al.  Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine , 2018, Lupus.

[41]  D. Yoon,et al.  Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice , 2018, BioMed research international.

[42]  J. Narbutt,et al.  Seizures as a rare adverse effect of chloroquine therapy in systemic lupus erythematosus patients: a case report and literature survey , 2018, Postepy dermatologii i alergologii.

[43]  F. Roubille,et al.  Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature , 2018, Drug Safety.

[44]  D. Gustafson,et al.  Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[45]  I. Bertolozzi,et al.  Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes , 2018, Front. Pharmacol..

[46]  A. Schultz,et al.  Side effects of medications used to treat childhood interstitial lung disease. , 2018, Paediatric respiratory reviews.

[47]  N. Curtis,et al.  The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms , 2018, Front. Immunol..

[48]  M. Clowse,et al.  Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH‐Deficient Patients , 2018, Arthritis care & research.

[49]  Wei Zhang,et al.  Azithromycin Causes a Novel Proarrhythmic Syndrome , 2017, Circulation: Arrhythmia and Electrophysiology.

[50]  A. Nicholson,et al.  European protocols for the diagnosis and initial treatment of interstitial lung disease in children , 2015, Thorax.

[51]  X. Mariette,et al.  Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus , 2015, Arthritis & rheumatology.

[52]  H. Yamazaki,et al.  Azithromycin Can Prolong QT Interval and Suppress Ventricular Contraction, but Will Not Induce Torsade de Pointes , 2015, Cardiovascular Toxicology.

[53]  A. Sié,et al.  Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults , 2014, Malaria Journal.

[54]  D. Browning Pharmacology of Chloroquine and Hydroxychloroquine , 2014, Hydroxychloroquine and Chloroquine Retinopathy.

[55]  Semicyuc,et al.  Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia , 2013, Intensive Care Medicine.

[56]  Azithromycin and risk of sudden cardiac death: Guilty as charged or falsely accused? , 2013 .

[57]  B. Gazzard,et al.  Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. , 2012, JAMA.

[58]  Y. Jang,et al.  Macrolide Therapy in Respiratory Viral Infections , 2012, Mediators of inflammation.

[59]  C Michael Stein,et al.  Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.

[60]  D. Chandramohan,et al.  Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy , 2011, Expert opinion on drug metabolism & toxicology.

[61]  M. A. van de Laar,et al.  An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. , 2009, Clinical therapeutics.

[62]  Jae-Won Park,et al.  Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by Plasmodium vivax , 2009, Antimicrobial Agents and Chemotherapy.

[63]  M. Namazi The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine , 2009, Lupus.

[64]  M.-C. Husson Thériaque® : base de données indépendante sur le médicament, outil de bon usage pour les professionnels de santé , 2008 .

[65]  Dustin E. Schones,et al.  Priming for T helper type 2 differentiation by interleukin 2-mediated induction of IL-4 receptor α chain expression , 2008, Nature Immunology.

[66]  Paul C. Lee,et al.  A 75-year-old man with significant bleeding after transbronchial biopsy , 2008, Platelets.

[67]  M. Husson [Theriaque: independent-drug database for good use of drugs by health practitioners]. , 2008, Annales pharmaceutiques francaises.

[68]  J. Fries,et al.  Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. , 2007, JAMA.

[69]  E. Randinitis,et al.  LACK OF A PHARMACOKINETIC INTERACTION BETWEEN AZITHROMYCIN AND CHLOROQUINE , 2006 .

[70]  J. Sung,et al.  Cardiovascular complications of severe acute respiratory syndrome , 2006, Postgraduate Medical Journal.

[71]  T. Hasegawa,et al.  Possible Involvement of the Drug Transporters P Glycoprotein and Multidrug Resistance-Associated Protein Mrp2 in Disposition of Azithromycin , 2004, Antimicrobial Agents and Chemotherapy.

[72]  Martin Traebert,et al.  Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. , 2004, European journal of pharmacology.

[73]  S. Tett,et al.  Population Pharmacokinetics of Hydroxychloroquine in Patients With Rheumatoid Arthritis , 2003, Therapeutic drug monitoring.

[74]  R. Day,et al.  Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. , 2002, The Journal of rheumatology.

[75]  G. Breithardt,et al.  Divergent Proarrhythmic Potential of Macrolide Antibiotics Despite Similar QT Prolongation: Fast Phase 3 Repolarization Prevents Early Afterdepolarizations and Torsade de Pointes , 2002, Journal of Pharmacology and Experimental Therapeutics.

[76]  F. Strle,et al.  Is azithromycin treatment associated with prolongation of the Q-Tc interval? , 2002, Wiener klinische Wochenschrift.

[77]  D. Fish,et al.  Possible Interaction Between Intravenous Azithromycin and Oral Cyclosporine , 2001, Pharmacotherapy.

[78]  J. Westphal Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. , 2001, British journal of clinical pharmacology.

[79]  R. Huupponen,et al.  Influence of hydroxychloroquine on the bioavailability of oral metoprolol. , 2000, British journal of clinical pharmacology.

[80]  J. Abisheganaden,et al.  Effect of clarithromycin on experimental rhinovirus-16 colds: a randomized, double-blind, controlled trial. , 2000, The American journal of medicine.

[81]  M. Weisman,et al.  Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. , 1999, Arthritis and rheumatism.

[82]  Z. Güneş,et al.  Improvement in cyclosporine A associated gingival hyperplasia with azithromycin therapy. , 1996, Transplantation proceedings.

[83]  Furst De Clinical Pharmacology of Combination DMARD Therapy in Rheumatoid Arthritis , 1996 .

[84]  D. Furst Clinical pharmacology of combination DMARD therapy in rheumatoid arthritis. , 1996, The Journal of rheumatology. Supplement.

[85]  F. Breedveld,et al.  Chloroquine inhibits T cell proliferation by interfering with IL‐2 production and responsiveness , 1995, Clinical and experimental immunology.

[86]  E. Singlas [Clinical pharmacokinetics of azithromycin]. , 1995, Pathologie-biologie.

[87]  D. Furst Optimizing Combination Chemotherapy for Rheumatoid Arthritis , 1993, Annals of the New York Academy of Sciences.

[88]  W. Robberecht,et al.  Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction. , 1989, Archives of neurology.

[89]  J. R. Loudon Hydroxychloroquine and postoperative thromboembolism after total hip replacement. , 1988, The American journal of medicine.

[90]  R. Day,et al.  A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. , 1988, British journal of clinical pharmacology.